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1. Introduction
Arachidonic acid is the most abundant polyunsaturated fatty
acid in the phospholipid bilayer of cell membranes. This second-
messenger molecule is released by phospholipase A2 in activated
cells and further metabolized in different eicosanoids by the
2, on the other hand, is usually absent in most tissues (with the
exception of kidney, parts of the brain, and gravid uterus where
COX-2 is constitutive) but its expression can be readily induced by
numerous stimuli such as growth factors, tumor promoters, or
cytokines [1,2]. The earliest expression of COX-2 is detected in
stromal cells, but it also can be found in multiple cells, like
A B S T R A C T
Cyclooxygenases (COXs) are the key enzymes in the biosynthesis of prostanoids. COX-1 is a constitutive
enzyme while the expression of COX-2 is highly stimulated in the event of inﬂammatory processes,
leading to the production of large amounts of prostaglandins (PGs), in particular PGE2 and PGI2, which
are pro-inﬂammatory mediators.
Lipoxygenases (LOXs) are enzymes that produce hydroxy acids and leukotrienes (LTs). 5-LOX
metabolizes arachidonic acid to yield, among other products, LTB4, a potent chemoattractantmediator of
inﬂammation.
The aim of the present work was to evaluate the anti-inﬂammatory potential of 2-styrylchromones
(2-SC), a chemical family of oxygen heterocyclic compounds, vinylogues of ﬂavones (2-phenylchro-
mones), by studying their COX-1 and COX-2 inhibitory capacity as well as their effects on the LTB4
production by stimulated human polymorphonuclear leukocytes (PMNL).
Some of the tested 2-SC were able to inhibit both COX-1 activity and LTB4 production which makes
them dual inhibitors of the COX and 5-LOX pathways. The most effective compounds in this study were
those having structural moieties with proved antioxidant activity (30,40-catechol and 40-phenol
substituted B-rings).
This type of compounds may exhibit anti-inﬂammatory activity with a wider spectrum than that of
classical non-steroidal anti-inﬂammatory drugs (NSAIDs) by inhibiting 5-LOX product-mediated
inﬂammatory reactions, towards which NSAIDs are ineffective.cyclooxygenase and lipoxygenase pathways (Fig. 1). Cyclooxy-
genases (COXs) are the key enzymes in the biosynthesis of
prostanoids. In mammalian cells, COXs exist in at least two
isoforms (COX-1 and COX-2). COX-1 is a constitutive enzyme,
expressed in almost every cell type, responsible for the physio-
logical production of prostaglandins (PGs) i.e., PGI2, PGE2, PGF2a,
and PGD2, in diverse organs and thromboxane A2 in platelets. COX-
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E-mail address: egracas@ff.up.pt (E. Fernandes).epithelial, endothelial, and stromal cells in several types of tumors
[3]. In addition, COX-2 is highly expressed by cells that are involved
in inﬂammation (e.g., neutrophils, macrophages, monocytes, mast
cells, synoviocytes), emerging as the isoform primarily responsible
for the synthesis of the prostanoids involved in pathological
processes, such as acute and chronic inﬂammatory states. These
inﬂammation-related cell types can be stimulated by lipopoly-
saccharide, phorbol esters, cytokines, or growth factors, producing
large amounts of PGs, in particular PGE2 and PGI2, which are pro-
inﬂammatory mediators that increase vascular permeability and
promote edema at the sites of inﬂammation. Furthermore, these
Fig. 1. Metabolism of arachidonic acid by the cyclooxygenase and 5-lipoxygenase pathways. (*) 5-Lipoxygenase-activating protein.PGs are involved in the nociception of the inﬂammatory pain [4].
Thus, COX-2 isoform has been associated with acute and chronic
inﬂammatory disorders [5] as well as in the carcinogenesis and
tumor progression [3].
Lipoxygenases (LOXs) are enzymes that produce hydroxy acids
and leukotrienes (LTs). From the LOXs existent in the mammalian
tissues, 5-LOX, which ismainly found in cells of myeloid origin, i.e.,
polymorphonuclear leukocytes (PMNL), mast cells, macrophages,
is themost implicated in inﬂammatory and allergical disorders [6].
5-LOX metabolizes arachidonic acid to yield 5(S)-hydroxy-
6,8,11,14-eicosatetraenoic acid (5-HETE), which is further meta-
bolized to the bioactive 5-oxo-6,8,11,14-eicosatetraenoic acid (5-
oxo-ETE) by PMNL 5-hydroxyeicosanoid dehydrogenase [7], and
various LTs (LTA4-LTE4) [8]. 5-oxo-ETE and LTB4, produced by
PMNL, are potent chemoattractant mediators of inﬂammation.
LTB4 stimulates neutrophil chemotaxis, enhances neutrophil-
endothelial interactions, and stimulates neutrophil activation,
leading to degranulation and the release of mediators, enzymes,
and superoxide radicals [9], while 5-oxo-ETE is much more active
than LTB4 as an eosinophil chemoattractant [10]. LTC4, LTD4 and
LTE4, also known as Cys-leukotrienes, have shown to be essential
mediators in asthma pathophysiology [11].
Although the major pathophysiological implication of LTs was
considered to be the bronchial asthma, these eicosanoids
contribute to the pathogenesis of other human inﬂammatory
diseases such as rheumatoid arthritis, inﬂammatory bowel disease,
Crohn’s disease, and psoriasis (see [11–13] for reviews). Recently,
the 5-LOX pathway has also been associated with atherosclerosis,
osteoporosis and certain types of cancer like prostate cancer [12].
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the most
commonly used remedy in inﬂammatory disorders. However, they
cause several adverse effects, the most important being gastric
injury up to gastric ulceration, renal failure and asthma [14]. On the
other hand, the COX-2 selective drugs, generically known as
COXIBs, have recently been a cause of controversy due to the
enhanced cardiovascular risk they carry [13]. Thus, alternative
therapeutic solutions, with similar anti-inﬂammatory potency but
with fewer side effects, are needed, especially for the control of
chronic inﬂammatory diseases, which implicate longer therapies.2-Styrylchromones (2-SC) are a chemical family of oxygen
heterocyclic compounds, vinylogues of ﬂavones (2-phenylchro-
mones), whose occurrence in nature has been reported [15,16].
Natural and synthetic 2-styrylchromones have been tested in
different chemical and biological systems, showing activities with
potential therapeutic applications [17–24]. The anti-inﬂammatory
potential of 2-styrylchromones, concerning their interference with
the arachidonic acidmetabolic pathways, has not been explored so
far. However, this may represent a promising ﬁeld of research
considering the potent inhibition of eicosanoids production by
certain ﬂavonoids containing structural similarities with 2-SC (see
[25] for review). Therefore, the purpose of this work was to
evaluate the inhibition of COX-1 and COX-2 activities, in a cell-free
system, as well as the inhibition of LTB4 production, in human
PMNL, by a group of 2-SC (Fig. 2).
2. Material and methods
2.1. Reagents
All the chemicals and reagents were of analytical grade. Hanks’
balanced salt solution (HBSS), Dulbecco’s phosphate buffered
saline, DMSO, nordihydroguaiaretic acid (NDGA), calcium iono-
phore (A23187), indomethacin, iron(II) chloride, iron(III) chloride,
ascorbic acid, and arachidonic acid were obtained from Sigma–
Aldrich (Steinheim, Germany). The ‘‘Leucotriene B4 Enzyme
Immunoassay (EIA) Kit’’ and ‘‘COX Inhibitor Screening Assay’’
were obtained from Cayman Chemical Co., Ann Arbor, MI, USA.
Celecoxib was an offer from Pﬁzer. Potassium ferricyanide
[K3Fe(CN)6] and trichloroacetic acid were obtained from Merck
(Darmstadt, Germany).
2-Styrylchromones 1A–1D, 2A–2D and 3A–3D were synthe-
sised by the three step Baker–Venkataramanmethod, starting from
the O-protected 20-hydroxyacetophenones and cinnamoyl chlor-
ides [26]. The ﬁrst step involves the O-acylation of appropriate 20-
hydroxyacetophenones with cinnamoyl chloride derivatives to
give 20-cinnamoyloxyacetophenones. These intermediates were
converted into 5-aryl-3-hydroxy-1-(2-hydroxyaryl)-2,4-penta-
dien-1-ones by the base-catalysed Baker–Venkataraman rearran-
Fig. 2. Chemical structures of the tested 2-SC.gement [27–29]. The cyclodehydration of theseb-diketoneswith a
mixture of DMSO and a catalytic amount of iodine or p-
toluenesulfonic acid gives polybenzyloxy-2-SC, which were
debenzylated by treatment with hydrogen bromide in acetic acid
at reﬂux, to give the expected hydroxy-2-SC 1A–1D, 2A–2D and
3A–3D.
2.2. Equipment
A microplate reader (Synergy HT, BIO-TEK), was used to
perform the spectrophotometric readings in all the assays.
2.3. Determination of LTB4 production by human PMNL
Human PMNL were isolated from peripheral blood of healthy
volunteers as previously described [30]. Neutrophil suspensions
(5  106 cells/mL) in HBSS were pre-incubated at 37 8C for 10 min
with the 2-SC (25 and 10 mM) or with the lipoxygenase inhibitor,
NDGA (1mM). The cellswere subsequently incubatedwith A23187
(5mM) and arachidonic acid (10mg/mL) for 8 min. The reactions
were stopped by the addition of cold methanol. Samples were
subsequently centrifuged at 13,000  g for 1 min, and the super-
natants were stored at70 8C until analysis. The amount of LTB4 in
the sampleswasmeasured using the abovementioned commercial
EIA kit, according to the manufacturer’s instructions. The results
were expressed as the percent inhibition of control LTB4
production. At least four determinations were done for each
experiment.2.4. COX-1 and COX-2 inhibition assays
The inhibition of COX-1 (ovine) and COX-2 (human recombi-
nant) by 2-SC was determined in a cell-free system by quantifying
the levels of PGF2a, produced by catalysis of arachidonic acid, using
the above mentioned speciﬁc EIA kit according to the manufac-
turer’s instructions. The COX inhibitors indomethacin and
celecoxib were used as positive controls. The results were
expressed as the percent inhibition of control COX-1 or COX-2
activity. At least four determinations were done for each
experiment.
2.5. Determination of the reducing power
The reductive potential of 2-SC was determined according to a
previously described method [31]. Test compounds, in 1 mL of a
ultrapure water/DMSO 3:1 solution, were mixed with phosphate
buffer (2.5 mL, 0.2 M, pH 6.6) and potassium ferricyanide
[K3Fe(CN)6] (2.5 mL, 1% w/v). The mixture was incubated at
50 8C for 20 min. A portion (2.5 mL) of trichloroacetic acid (10% w/
v) was added to the mixture, which was then centrifuged for
10 min at 3000 g. The upper layer of the solution (2.5 mL) was
mixed with ultrapure water (2.5 mL) and FeCl3 (0.5 mL, 0.1% w/v),
and the absorbance was measured at 700 nm. Higher absorbance
of the reaction mixture indicated greater reducing power. Ascorbic
acid was used as standard compound.
2.6. Determination of metal chelating activity
The metal chelating activity was assessed by monitoring the
changes in UV–vis spectrum of 2-SC after addition of Fe(II) [32].
Titration experiments were performed by sequential additions of
2mL of FeCl2 solution (300 mM stock solution) to 300mL of a
10 mM (ﬁnal concentration) 2-SC solution. The titrations were
performed in phosphate buffer 20 mM, pH 7.2.
2.7. Cytotoxicity
The effect of the 2-SC on the cell viability was assessed by the
trypan blue exclusion method and by the release of LDH (as a
measure of cell membrane integrity). The LDH activity was
determined by following the rate of oxidation of NADH at 340 nm.
2.8. Statistical analysis
Statistical analysis was performed by one-way analysis of
variance (ANOVA) followed by Dunnett’s multicomparison test
using GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego California, USA, http://www.graphpad.com.
When comparing with control group, values of P less than 0.05
were considered signiﬁcant.
Pearson correlation tests were performed using GraphPad
Prism version 5.00 for Windows, GraphPad Software, San Diego
California, USA, http://www.graphpad.com.
3. Results
3.1. Inhibition of LTB4 production by human PMNL
All the tested 2-SC showed to have inhibitory effects on the LTB4
production by human PMNL. 2-SC from group 1 were more
effective inhibitors of LTB4 production than the correspondent
compounds from the other groups. Compounds 1A, 1C, and 1D, at
the concentration of 25mM, were able to inhibit the LTB4
production with a 90% effect, while the compound 1B showed
a 66.0  12.4% effect at the same concentration (Fig. 3). These
Fig. 3. Inhibition of human PMNL production of LTB4 by 2-SC (25mM) and NDGA
(1 mM) determined by EIA. Each value represents mean  SEM of at least four
experiments performed in duplicate. (***) P < 0.001, (**) P < 0.01, (*) P < 0.05,
signiﬁcantly different from control.
Fig. 4. Inhibition of COX-1 activity by 2-SC, determined by EIA. Each value
represents mean  SEM of at least 4 experiments performed in duplicate. (***)
P < 0.001, (*) P < 0.05, signiﬁcantly different from control.
Fig. 5. Reducingactivityof2-SCandascorbic acid (AA).All thecompoundswere tested
at the ﬁnal concentration of 25mM. Each value represents mean SEM of triplicate
measurements. (***) P < 0.001, (*) P < 0.05, signiﬁcantly different from control.compounds were still very effective at the lowest tested concentra-
tion (10 mM), 1C being the strongest inhibitor (80.9  10.1% effect,
P < 0.001) and 1B the weakest inhibitor (38.5  11.8% effect,
P < 0.01). 1A showed a 63.9  9.2% effect (P < 0.001) and 1D showed
a 62.3  7.9% effect (P < 0.001). The compounds from group 2 were
more effective inhibitors than the correspondent compounds from
group 3. 2C was the most effective compound from group 2, reaching
a 78.0  9.0% effect at the concentration of 25 mM, while 3D was the
most effective compound from group 3, showing a 48.9  10.3% effect
at the same concentration (Fig. 3). These compounds were still
signiﬁcantly effective at the concentration of 10 mM, where 2C
showed an effect of 50.6  11.9% (P < 0.001) and 3D showed an effect
of 42.2  9.6% (P < 0.01). The compounds 1B, 2B, and 3B were the
weakest inhibitors in the respective groups. The 5-LOX inhibitor
NDGA (1 mM) reached a 76.1  11.0% inhibitory effect (Fig. 3).
3.2. Inhibition of COX-1 and COX-2 in a cell-free system
All 2-SC from group 1 were able to inhibit COX-1. 1A
signiﬁcantly inhibited the enzyme’s activity at the concentrations
of 100 mM (46.0  5.6%) and 250 mM (74.4  12.8%). 1B inhibition
was only signiﬁcant at 250 mM (54.2  12.6%). Due to solubility
issues, compounds 1C and 1D could only be tested at a maximum
concentration of 100 mM, with 1D showing a signiﬁcant inhibition
(24.6  6.4%). From group 2, only 2A and 2B where shown to inhibit
COX-1, when tested at the concentration of 250 mM, 2A being a
signiﬁcant inhibitor (66.5  11.4%) (Fig. 4). No other 2-SC was able to
inhibit COX-1. None of the studied 2-SC inhibited COX-2 at the tested
concentrations (100 mM and 250 mM). Indomethacin (1 mM) inhib-
ited COX-1 (26.6  6.6%) and COX-2 (92.6  2.1%) and the selective
COX-2 inhibitor celecoxib (10 mM) could only inhibit this isoenzyme
(68.2  3.0%).
3.3. Reducing power
From the tested 2-SC, compounds 1A–1D and 2B were able to
reduce, signiﬁcantly, ferric ion. Compounds from group 1 were
shown to be more efﬁcient reducers than ascorbic acid (Fig. 5).
3.4. Metal chelating activity
The UV–vis absorption spectrum of 2-SC 1A–1D showed a
common absorption peak at 380 nm which presented bath-ochromic shift upon addition of growing amounts of Fe(II),
increasing gradually until the 400 nm (Fig. 6).
No relevant changes were observed in the UV–vis spectrum of
2-SC from groups 2 and 3 upon addition of Fe(II).
3.5. Cytotoxicity
None of the 2-SC caused an increased in the release of LDH
compared to the control. The cell viability, assessed by the trypan
blue exclusion method, was above 95% for all the compounds.
3.6. Correlations between the inhibition of LTB4 production and
scavenging activity
Signiﬁcant correlations were found between the inhibition of
LTB4 production, described in Section 3.1, and the scavenging
activity for singlet oxygen (1O2), and peroxynitrite anion (ONOO
)
(these assays were performed in a previous work [24]).
4. Discussion
In this work, 2-SC were tested for their anti-inﬂammatory
potential, through their capacity to interfere with the arachidonic
Fig. 6.UV–vis absorption spectrum of 10mMof compounds (A) 1A, (B) 1B, (C) 1C, and (D) 1D in the presence of 0, 2, 4, 6, 8, 10, 12, 14, and 16 mMof Fe(II), in 20 mMphosphate
buffer, pH 7.2. The direction of the arrows indicates crescent amounts of Fe(II). Insets: titration curves.acid metabolic pathways, in particular, the COX-1 and COX-2
pathways, studied in a cell-free system, and 5-LOX pathway,
studied in a cellular system using human PMNL. All the studied
compounds were shown to inhibit the LTB4 production by human
leukocytes, especially those with a catechol substituted B-ring.
This biological effect of 2-SC is shown for the ﬁrst time, in the
present study. As previously mentioned, 2-SC are vinylogues of
ﬂavones. Accordingly, Yoshimoto et al. [33] had previously found
that the ﬂavone structure represents a pharmacophore for 5-LOX
inhibitory activity. In a recent theoretical study [34], a correlation
was found between the lipoxygenase inhibitory activity of
ﬂavonoid molecules and their planar character, which probably
facilitates the access, through a hydrophobic cavity, to the catalytic
site of the enzyme. Considering this rationale, the planar character
of 2-SC [16,29,35], conferred by the styryl link between the B-ring
and the C-ring, may contribute to their effectiveness as 5-LOX
inhibitors.
Several mechanisms, other than a direct inhibition of 5-LOX,
can explain the observed inhibition of LTB4 production by 2-SC.
These include the inhibition of phospholipase A2, and thus of the
arachidonic acid release, the inhibition of LTA4 hydrolase, or the
blockade of 5-lipoxygenase activating protein. Nevertheless, it is
conceivable that 2-SC, in conformity with ﬂavonoids and other
phenolic compounds, act as redox 5-LOX inhibitors. Catalytically
active 5-LOX requires the conversion of Fe(II) to Fe(III), conferred
by certain lipid hydroperoxides (LOOH). Most 5-LOX inhibitors act
at the catalytic domain by reducing or chelating the active-site iron
or by scavenging radical intermediates in the redox cycle of the
iron [6,25]. Accordingly, the reduction of ferric ion is a possible
mechanism of inhibition of LTB4 production by 2-SC, since the
most effective compounds (1A–1D) also behaved as strong
reducers (Fig. 3 vs. Fig. 5). Indeed, signiﬁcant correlation was
found between the inhibition of LTB4 production and the reducing
power of the tested compounds (Table 1). On the other hand, the
spectral changes of those compounds upon addition of Fe(II)
indicate the formation of iron complexes. The similar changes in all
the compounds indicate that the Fe(II)-binding site is between the
ortho-hydroxyl groups in the B-ring, considered to be one ‘‘iron
binding motif’’ in ﬂavonoid molecules [32,36]. Furthermore, the
Fe(II) titration curves reveal the formation of 1:2 Fe(II):compound
complexes (Fig. 6). Besides indicating a possible mechanism of
inhibition of LTB4 production, themetal chelating capacity of the 2-SC from group 1, shown here for the ﬁrst time, is also a very
important indicator of their antioxidant activity. Finally, the
capacity of some 2-SC to scavenge reactive oxygen species (ROS)
and reactive nitrogen species (RNS), demonstrated in a previous
study [24], is also likely to contribute to their LTB4 production
inhibitory effect. Noteworthy, signiﬁcant correlations were found
between the inhibition of LTB4 production observed in the present
study and the scavenging activity for singlet oxygen (1O2), and
peroxynitrite anion (ONOO) reported before (Table 1).
2-SC 1A, 1B, 1D and 2A where shown to signiﬁcantly inhibit
COX-1. This is also the ﬁrst time that such biological activity of 2-SC
is disclosed. On the other hand, none of the tested compounds was
able to inhibit COX-2. Still, it is conceivable that this kind of effect
might be seen at higher concentrations in accordance to what has
been previously observed with a structural-similar compound
(7,30,40-trihydroxyﬂavone) [37]. However, due to solubility issues,
the studied 2-SC could not be tested at higher concentrations. On
the other hand, several ﬂavonoids have previously shown to inhibit
COX-2 expression (see [38] for review). The ﬂavonoid’s structural
features considered by others [39] as relevant for this kind of
activity are shared by some of the tested 2-SC, speciﬁcally
compounds 1A and 2A. Thus, 2-SC, particularly the two referred
compounds, may still be COX-2 inhibitors in vivo despite the
negative results obtained in the present study.
The mechanism through which 2-SC inhibit COX-1 is likely to
consist in the scavenging of the radical intermediates involved in
COX enzyme catalysis, especially the phenoxy radical formed on a
tyrosine residue, according to what has been previously suggested
for other compounds with antioxidant moieties [40]. This
mechanism is consistent with the fact that the only effective 2-
SC were those which have shown higher ROS and RNS scavenging
effects in our previous study [24].
The capacity of some of the tested 2-SC to inhibit both COX-1
and LOX pathways plays in favour of their potential use as effective
and secure anti-inﬂammatory drugs, when compared to the
commonly used NSAIDs and COXIBs. It is well known that NSAIDs
may cause several adverse effects such as gastric ulceration, renal
failure and asthma. On the other hand, the safety of selective
COXIBs has been recently questioned due to the apparent
association of these drugs with an increased risk of cardiovascular
events. The cardiovascular adverse effects are probably due to a
reduction on the levels of PGI2, an important anti-thrombotic
Table 1
Pearson correlations between the inhibition of LTB4 production and the reducing
activity and between the LTB4 production and the scavenging activity against
1O2
(IC30) and ONOO
 (with and without bicarbonate) (IC50) [24] of the tested 2-SC.
Graph Pearson (r)
0.8254*
0.7951*
0.8482**
0.9056**
(a) Without bicarbonate; (b) with bicarbonate.
* Signiﬁcant at P < 0.05.
** Signiﬁcant at P < 0.01.eicosanoid, in concomitance to an excess of thromboxane A2,
which has the opposite effect [41–43]. Considering gastric effects,
COX-2 selective inhibitors can delay the repair of existing
gastrointestinal damage caused by ulcers, most likely by reducing
the synthesis of PGs that are thought to play an important role in
the healing process [44]. In fact, the inhibition of COX pathway has
to be interpreted with careful because of the diversity of COX-
derived mediators with different properties. Indeed, the PGE2,
which has been mostly considered a pro-inﬂammatory mediator,
has, on the other hand, given proves of involvement in anti-
inﬂammatory and pro-resolving responses [45–47]. Furthermore,
the COX inhibition shunts the arachidonic acidmetabolism toward
the 5-LOX pathway enhancing the gastric mucosal damages due to
the augmented production of LTB4 [44,48] and inducing adverse
reactions in patients with asthma as a result of the cys-LTs
overgeneration [44].
According to Bertolini et al. [14], dual acting anti-inﬂammatory
drugs may represent a breakthrough in the treatment of rheumatic
diseases, in view of several important arguments: (i) the same
molecule (i.e., one drug alone) inhibits both COXs and 5-LOX; (ii)the inhibition of both COX isoforms ensures a high anti-
inﬂammatory efﬁcacy and the concurrent preservation of the
cardiovascular protective effects; (iii) the simultaneous inhibition
of 5-LOX prevents pro-inﬂammatory and gastrointestinal dama-
ging effects of leukotrienes. From our point of view, the use of dual
inhibitors of the COX/5-LOX pathways seems advantageous to the
treatment of other inﬂammatory disorders beyond rheumatic
diseases. In fact, this type of compounds may exhibit anti-
inﬂammatory activity with a wider spectrum than that of classical
NSAIDs by inhibiting 5-LOX product-mediated inﬂammatory
reactions towards which NSAIDs are ineffective [44].
Importantly, it has beendemonstrated that the antioxidant effect
of many NSAIDs may contribute to their therapeutic effectiveness
[30,49–51]. Thus, the strongantioxidant effectsof2-SCwill certainly
contribute to their anti-inﬂammatory efﬁcacy in vivo.
In conclusion, in the present study, several of the tested 2-SC
were shown, for the ﬁrst time, to prevent LTB4 production by
human leukocytes and to inhibit COX-1 activity. These effects,
together with the well known antioxidant properties of these
compounds may become a new therapeutic option in the
treatment of inﬂammatory processes.
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